Floatz logo

Lipitor

Advanced Renal Cell Carcinoma (RCC)

Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

297 Active assets in the Advanced Renal Cell Carcinoma (RCC) cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
INTERFERON-ALFA-2A
Central European Society for Anticancer Drug Research
Phase 3BB

View all 50 →

Same molecule, other indications

Lipitor is also rated in:

inherited lipid metabolism disorderDormant
A
Indicative ·
83 / 100
View asset →
hyperlipidemiaDormant
BBB
Indicative ·
79 / 100
View asset →
HypercholesterolemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →